• OPEN AN ACCOUNT
Indian Indices
Sensex
84,273.92 208.17
( 0.25%)
Global Indices
Nasdaq
50,149.26 12.58
(0.03%)
Dow Jones
6,984.17 30.87
(0.44%)
Hang Seng
57,678.97 1,315.03
(2.33%)
Nikkei 225
10,354.92 -31.31
(-0.30%)
Forex
USD-INR
90.44 0.11
(0.13%)
EUR-INR
106.84 0.33
(0.31%)
GBP-INR
123.03 0.35
(0.29%)
JPY-INR
0.58 0.00
(-0.07%)

EQUITY - MARKET SCREENER

Industry :  
BSE Code
ISIN Demat
Book Value()
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
EPS(TTM)
Face Value()
Div & Yield %
 

Lupin settles patent dispute with Astellas
Feb 10,2026
Lupin announced that the company and its wholly owned subsidiary, Lupin Pharmaceuticals Inc., USA, have entered into a settlement and license agreement with Astellas Pharma Inc., Astellas Ireland Co., and Astellas Pharma Global Development Inc. (collectively Astellas) in respect of a patent infringement dispute related to the company's product 'Mirabegron'.

Under the terms of the Agreement, Lupin will pay Astellas (1) USD 90 million, which includes a Prepaid Option Payment of USD 75 million, and (2) a Prepaid Per Unit License Fee for each unit of Lupin Product sold from the date of the settlement through September 2027. The settlement terms are confidential.